Circulating microRNAs as potential markers of human drug-induced liver injury

Hepatology

Volumn 54, Issue 5, 2011, Pages 1767-1776

  Starkey Lewis, Philip J ^a   Dear, James ^b,c   Platt, Vivien ^a   Simpson, Kenneth J ^d   Craig, Darren G N ^d   Antoine, Daniel J ^a   French, Neil S ^a   Dhaun, Neeraj ^e   Webb, David J ^e   Costello, Eithne M ^a   Neoptolemos, John P ^a   Moggs, Jonathan ^f   Goldring, Chris E ^a   Park, B Kevin ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c NPIS Edinburgh   (United Kingdom)

^d ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; CREATININE; MICRORNA; MICRORNA 122; MICRORNA 192; PARACETAMOL; UNCLASSIFIED DRUG;

ACETAMINOPHEN INDUCED ACUTE LIVER INJURY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTHROMBIN TIME; TOXIC HEPATITIS;

ACETAMINOPHEN; ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ANALGESICS, NON-NARCOTIC; BIOLOGICAL MARKERS; DIAGNOSTIC TECHNIQUES, DIGESTIVE SYSTEM; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; LIVER TRANSPLANTATION; MALE; MICRORNAS; MIDDLE AGED; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 80055038826     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24538     Document Type: Article

References (28)

1. Adler M, Hoffmann D, Ellinger-Ziegelbauer H, Hewitt P, Matheis K, Mulrane L, et al. Assessment of candidate biomarkers of drug-induced hepatobiliary injury in preclinical toxicity studies. Toxicol Lett 2010; 196: 1-11.
2. Antoine DJ, Williams DP, Jenkins AK, Regan SL, Sathish JG, Kitteringham NR, Park BK. High-mobility group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis, and apoptosis in vivo. Toxicol Sci 2009; 112: 521-531.
3. Amacher DE. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity. Toxicol Appl Pharmacol 2010; 245: 134-142.
4. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
5. Liang Y, Ridzon D, Wong L, Chen C. Characterization of microRNA expression profiles in normal human tissues. BMC Genomics 2007; 8: 166.
6. Chang J, Nicolas E, Marks D, Sander C, Lerro A, Buendia MA, et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 2004; 1: 106-113.
7. Girard M, Jacquemin E, Munnich A, Lyonnet S, Henrion-Caude A. miR-122, a paradigm for the role of microRNAs in the liver. J Hepatol 2008; 48: 648-656.
8. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009; 28: 3526-3536.
9. Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A 2009; 106: 4402-4407.
10. Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, et al. Acetaminophen-induced acute liver failure: results of a united states multicenter, prospective study. Hepatology 2005; 42: 1364-1372.
11. Lee WM. Acetaminophen and the U.S. acute liver failure study group: lowering the risks of hepatic failure. Hepatology 2004; 40: 6-9.
12. Ostapowicz G, Fontana RJ, Schioødt FV, Larson A, Davern TJ, Han SHB, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the united states. Ann Intern Med 2002; 137: 947-954.
13. Dhaun N, Macintyre IM, Melville V, Lilitkarntakul P, Johnston NR, Goddard J, Webb DJ. Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease. Hypertension 2009; 54: 113-119.
14. Zhang Y, Jia Y, Zheng R, Guo Y, Wang Y, Guo H, et al. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem 2010; 56: 1830-1838.
15. Ozkaya O, Genc G, Bek K, Sullu Y. A case of acetaminophen (paracetamol) causing renal failure without liver damage in a child and review of literature. Ren Fail 2010; 32: 1125-1127.
16. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008; 105: 10513-10518.
17. Mahn R, Heukamp LC, Rogenhofer S, Von Ruecker A, Müller SC, Ellinger J. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 2011; 77: 1265.e9-1265.e16.
18. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 2011; 108: 5003-5008.
19. Wang G, Tam LS, Li E, Kwan B, Chow KM, Luk C, et al. Serum and urinary free microRNA level in patients with systemic lupus erythematosus. Lupus 2011; 20: 493-500.
20. Wang F, Zheng Z, Guo J, Ding X. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol 2010; 119: 586-593.
21. Bihrer V, Friedrich-Rust M, Kronenberger B, Forestier N, Haupenthal J, Shi Y, et al. Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am J Gastroenterol 2011 May 24. doi: 10.1038/ajg.2011.161.
22. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific MicroRNAs from mouse. Curr Biol 2002; 12: 735-739.
23. Glinghammar B, Rafter I, Lindström AK, Hedberg JJ, Andersson HB, Lindblom P, et al. Detection of the mitochondrial and catalytically active alanine aminotransferase in human tissues and plasma. Int J Mol Med 2009; 23: 621-631.
24. Lindblom P, Rafter I, Copley C, Andersson U, Hedberg JJ, Berg AL, et al. Isoforms of alanine aminotransferases in human tissues and serum-differential tissue expression using novel antibodies. Arch Biochem Biophys 2007; 466: 66-77.
25. Skenderi KP, Kavouras SA, Anastasiou CA, Yiannakouris N, Matalas AL. Exertional rhabdomyolysis during a 246-km continuous running race. Med Sci Sports Exerc 2006; 38: 1054-1057.
26. Koutedakis Y, Raafat A, Sharp NCC, Rosmarin MN, Beard MJ, Robbins SW. Serum enzyme activities in individuals with different levels of physical fitness. J Sports Med Phys Fitness 1993; 33: 252-257.
27. Saheki T, Komorizono K, Miura T, Ichiki H, Yagi Y, Hashimoto S. Clearance of arginiosuccinate synthetase from the circulation in acute liver disease. Clin Biochem 1990; 23: 139-141.
28. Gatfield D, Le Martelot G, Vejnar CE, Gerlach D, Schaad O, Fleury-Olela F, et al. Integration of microRNA miR-122 in hepatic circadian gene expression. Genes Dev 2009; 23: 1313-1326.